Opinion|Videos|October 4, 2024
Overview of Recent Updates in Bispecific Therapy in R/R MM
The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss similarities/differences in mechanism of action, key efficacy endpoints and safety data:
- Teclistamab
- MajesTEC-1 (NEJM 2022)
- MajesTEC-1 Long-term Follow-up (ASCO 2024)
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5